3-Chloro-5-cyclohexyloxypyridine-4-carbaldehyde | 1289107-10-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-Chloro-5-cyclohexyloxypyridine-4-carbaldehyde
• 英文别名: 3-chloro-5-cyclohexyloxypyridine-4-carbaldehyde
• CAS: 1289107-10-3
• 化学式: C₁₂H₁₄ClNO₂
• 分子量: 239.702
• InChiKey: DNRJDFPRYKRMCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Chloro-5-cyclohexyloxypyridine-4-carbaldehyde 在 N-甲基吗啉氧化物 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 1-(3-Chloro-5-cyclohexyloxypyridin-4-yl)ethanone
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2
  [FR] PYRAZOLOPYRIDINES EN TANT QU'INHIBITEURS DE LA KINASE LRRK2

  摘要：

  一种具有化学式la或化学式lb的化合物，或其在药学上可接受的盐或酯，其中R1选择自：芳基；杂环芳基；-NHR3；融合芳基-C4-7-杂环烷基；-CONR4R5；-NHCOR6；-C3-7-环烷基；-0-C3-7-环烷基；-NR3R6；以及可选择地取代的-C1-6烷基；其中所述的芳基、杂环芳基、融合芳基-C4-7-杂环烷基和C4-7-杂环烷基均可选择地取代；Q选择自CN、卤素，或选择自C1-6-烷基、C3-7-环烷基、杂环烷基、芳基和杂环芳基，每种均可选择地取代一个或多个取代基A；R2选择自氢、芳基、C1-6-烷基、C2-6-烯烃基、C3-7-环烷基、杂环芳基、C4-7-杂环烷基和卤素，其中所述的C1-6-烷基、C2-6-烯烃基、芳基、杂环芳基和C4-7-杂环烷基均可选择地取代；R3选择自芳基、杂环芳基、C4-7-杂环烷基、C3-7-环烷基、融合芳基-C-杂环烷基和C1-6-烷基，每种均可选择地取代；R4和R5各自独立地为氢，或可选择地取代的C3-7-环烷基、芳基、杂环芳基、C1-6-烷基或C3-6-杂环烷基；或R4和R5与其连接的N一起形成一个C3-6-杂环烷基环；每个R6独立地选择自C1-6-烷基、C3-7-环烷基、C-杂环烷基、芳基和杂环芳基，每种均可选择地取代；每个R7选择自氢、可选择地取代的C1-6-烷基和C3-7-环烷基；每个R8和R9各自独立地为氢或可选择地取代的C1-6-烷基；或R8和R9与其连接的N一起形成一个C4-6-杂环烷基；每个R10选择自C3-7-环烷基和可选择地取代的C1-6-烷基；每个R11独立地选择自C1-6-烷基、C3-7-环烷基、C1-6-烷基-C3-7-环烷基、C4-7-杂环烷基、芳基和杂环芳基，每种均可选择地取代；A选择自卤素、-NR4S02R5、-CN、-OR6、-NR4R5、-NR7R11、羟基、-CF3、-CONR4R5、-NR4COR5、-NR7(CO)NR4R5、-N02、-C02H、-C02R6、-S02R6、-S02NR4R5、-NR4COR5、-NR4COOR5、6-烷基和-COR6。进一步涉及到具有化学式la和lb的化合物的制药组合物、治疗用途和制备过程。

  公开号：

  WO2011141756A1
• 作为产物：
  描述：

  环己醇 在 正丁基锂 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 反应 53.0h， 生成 3-Chloro-5-cyclohexyloxypyridine-4-carbaldehyde
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2
  [FR] PYRAZOLOPYRIDINES EN TANT QU'INHIBITEURS DE LA KINASE LRRK2

  摘要：

  一种具有化学式la或化学式lb的化合物，或其在药学上可接受的盐或酯，其中R1选择自：芳基；杂环芳基；-NHR3；融合芳基-C4-7-杂环烷基；-CONR4R5；-NHCOR6；-C3-7-环烷基；-0-C3-7-环烷基；-NR3R6；以及可选择地取代的-C1-6烷基；其中所述的芳基、杂环芳基、融合芳基-C4-7-杂环烷基和C4-7-杂环烷基均可选择地取代；Q选择自CN、卤素，或选择自C1-6-烷基、C3-7-环烷基、杂环烷基、芳基和杂环芳基，每种均可选择地取代一个或多个取代基A；R2选择自氢、芳基、C1-6-烷基、C2-6-烯烃基、C3-7-环烷基、杂环芳基、C4-7-杂环烷基和卤素，其中所述的C1-6-烷基、C2-6-烯烃基、芳基、杂环芳基和C4-7-杂环烷基均可选择地取代；R3选择自芳基、杂环芳基、C4-7-杂环烷基、C3-7-环烷基、融合芳基-C-杂环烷基和C1-6-烷基，每种均可选择地取代；R4和R5各自独立地为氢，或可选择地取代的C3-7-环烷基、芳基、杂环芳基、C1-6-烷基或C3-6-杂环烷基；或R4和R5与其连接的N一起形成一个C3-6-杂环烷基环；每个R6独立地选择自C1-6-烷基、C3-7-环烷基、C-杂环烷基、芳基和杂环芳基，每种均可选择地取代；每个R7选择自氢、可选择地取代的C1-6-烷基和C3-7-环烷基；每个R8和R9各自独立地为氢或可选择地取代的C1-6-烷基；或R8和R9与其连接的N一起形成一个C4-6-杂环烷基；每个R10选择自C3-7-环烷基和可选择地取代的C1-6-烷基；每个R11独立地选择自C1-6-烷基、C3-7-环烷基、C1-6-烷基-C3-7-环烷基、C4-7-杂环烷基、芳基和杂环芳基，每种均可选择地取代；A选择自卤素、-NR4S02R5、-CN、-OR6、-NR4R5、-NR7R11、羟基、-CF3、-CONR4R5、-NR4COR5、-NR7(CO)NR4R5、-N02、-C02H、-C02R6、-S02R6、-S02NR4R5、-NR4COR5、-NR4COOR5、6-烷基和-COR6。进一步涉及到具有化学式la和lb的化合物的制药组合物、治疗用途和制备过程。

  公开号：

  WO2011141756A1

文献信息

• PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2
  申请人：Chan Brayn

  公开号：US20130267513A1

  公开（公告）日：2013-10-10

  A compound of formula Ia or formula Ib, or a pharmaceutically acceptable salt or ester thereof, wherein R 1 is selected from: aryl; heteroaryl; —NHR 3 ; fused aryl-C 4-7 -heterocycloalkyl; —CONR 4 R 5 ; —NHCOR 6 ; —C 3-7 -cycloalkyl; -0-C 3-7 -cycloalkyl; —NR 3 R 6 ; and optionally substituted —C 1-6 alkyl; wherein said aryl, heteroaryl, fused aryl-C 4-7 -heterocycloalkyl and C 4-7 -heterocycloalkyl are each optionally substituted; Q is CN, halogen, or is selected from C 1-6 -alkyl, C 3-7 -cycloalkyl, heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted with one or more substituents A; R 2 is selected from hydrogen, aryl, C 1-6 -alkyl, C 2-6 -alkenyl, C 3-7 -cycloalkyl, heteroaryl, C 4-7 -heterocycloalkyl and halogen, wherein said C 1-6 -alkyl, Cz-B-alkenyl, aryl, heteroaryl and C 4-7 -heterocycloalkyl are each optionally substituted; R 3 is selected from aryl, heteroaryl, C 4-7 -heterocycloalkyl, C 3-7 -cycloalkyl, fused aryl-C-heterocycloalkyl and C 1-6 -alkyl, each of which is optionally substituted; R 4 and R 5 are each independently hydrogen, or optionally substituted C 3-7 -cycloalkyl, aryl, heteroaryl, C 1-6 -alkyl or C 3-6 -heterocycloalkyl; or R 4 and R 5 together with the N to which they are attached form a C 3-6 -heterocycloalkyl ring; each R 6 is independently selected from C 1-6 -alkyl, C 3-7 -cycloalkyl, C-heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted; each R 7 is selected from hydrogen, optionally substituted C 1-6 -alkyl and C 3-7 -cycloalkyl; each of R 8 and R 9 is independently hydrogen or optionally substituted C 1-6 -alkyl; or R 8 and R 9 together with the N to which they are attached form a C 4-6 -heterocycloalkyl; each R 10 is selected from C 3-7 -cycloalkyl and optionally substituted C 1-6 -alkyl; each R 11 is independently selected from C 1-6 -alkyl, C 3-7 -cycloalkyl, C 1-6 -alkyl-C 3-7 -cycloalkyl, C 4-7 -heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted; A is selected from halogen, —NR 4 S0 2 R 5 , —CN, —OR 6 , —NR 4 R 5 , —NR 7 R 11 , hydroxyl, —CF 3 , —CONR 4 R 5 , —NR 4 COR 5 , —NR 7 (CO)NR 4 R 5 , —N0 2 , —C0 2 H, —C0 2 R 6 , —S0 2 R 6 , —S0 2 NR 4 R 5 , —NR 4 COR 5 , —NR 4 COOR 5 , 6 -alkyl and —COR 6 . Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formulae Ia and Ib.

  公式Ia或公式Ib的化合物，或其药学上可接受的盐或酯，其中R1选自：芳基；杂环芳基；-NHR3；融合芳基-C4-7-杂环烷基；-CONR4R5；-NHCOR6；-C3-7-环烷基；-0-C3-7-环烷基；-NR3R6；和可选取代的-C1-6烷基；其中所述的芳基、杂环芳基、融合芳基-C4-7-杂环烷基和C4-7-杂环烷基均可选取代基；Q为CN、卤素，或选自C1-6烷基、C3-7-环烷基、杂环烷基、芳基和杂环芳基，每种基均可选取代基A；R2选自氢、芳基、C1-6烷基、C2-6烯基、C3-7-环烷基、杂环芳基、C4-7-杂环烷基和卤素，其中所述的C1-6烷基、C2-6烯基、芳基、杂环芳基和C4-7-杂环烷基均可选取代基；R3选自芳基、杂环芳基、C4-7-杂环烷基、C3-7-环烷基、融合芳基-C-杂环烷基和C1-6烷基，每种基均可选取代基；R4和R5各自独立地为氢，或可选取代的C3-7-环烷基、芳基、杂环芳基、C1-6烷基或C3-6-杂环烷基；或R4和R5与它们连接的N一起形成C3-6-杂环烷基环；每个R6各自选自C1-6烷基、C3-7-环烷基、C-杂环烷基、芳基和杂环芳基，每种基均可选取代基；每个R7选自氢、可选取代的C1-6烷基和C3-7-环烷基；每个R8和R9各自独立地为氢或可选取代的C1-6烷基；或R8和R9与它们连接的N一起形成C4-6-杂环烷基；每个R10选自C3-7-环烷基和可选取代的C1-6烷基；每个R11各自独立地选自C1-6烷基、C3-7-环烷基、C1-6-烷基-C3-7-环烷基、C4-7-杂环烷基、芳基和杂环芳基，每种基均可选取代基；A选自卤素、-NR4S02R5、-CN、-OR6、-NR4R5、-NR7R11、羟基、-CF3、-CONR4R5、-NR4COR5、-NR7(CO)NR4R5、-N02、-C02H、-C02R6、-S02R6、-S02NR4R5、-NR4COR5、-NR4COOR5、6-烷基和-COR6。此外，还涉及公式Ia和Ib的化合物的制备过程、药物组合物和治疗用途。
• [EN] PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2<br/>[FR] PYRAZOLOPYRIDINES EN TANT QU'INHIBITEURS DE LA KINASE LRRK2
  申请人：MEDICAL RES COUNCIL TECHNOLOGY

  公开号：WO2011141756A1

  公开（公告）日：2011-11-17

  A compound of formula la or formula lb, or a pharmaceutically acceptable salt or ester thereof, wherein R1 is selected from: aryl; heteroaryl; -NHR3; fused aryl-C4-7-heterocycloalkyl; - CONR4R5; -NHCOR6; -C3-7-cycloalkyl; -0-C3-7-cycloalkyl; -NR3R6; and optionally substituted -C1-6 alkyl; wherein said aryl, heteroaryl, fused aryl-C4-7-heterocycloalkyl and C4-7- heterocycloalkyl are each optionally substituted; Q is CN, halogen, or is selected from C1-6-alkyl, C3-7-cycloalkyl, heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted with one or more substituents A; R2 is selected from hydrogen, aryl, C1-6-alkyl, C2-6-alkenyl,C3-7-cycloalkyl, heteroaryl, C4-7 heterocycloalkyl and halogen, wherein said C1-6-alkyl,, Cz-B-alkenyl, aryl, heteroaryl and C4-7-heterocycloalkyl are each optionally substituted;R3 is selected from aryl, heteroaryl, C4-7-heterocycloalkyl, C3-7- cycloalkyl, fused aryl-C-heterocycloalkyl and C1-6-alkyl, each of which is optionally substituted; R4 and R5 are each independently hydrogen, or optionally substituted C3-7- cycloalkyl, aryl, heteroaryl, C1-6-alkyl or C3-6-heterocycloalkyl; or R4 and R5 together with the N to which they are attached form a C3-6-heterocycloalkyl ring; each R6 is independently selected from C1-6-alkyl, C3-7 cycloalkyl, C-heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted; each R7 is selected from hydrogen, optionally substituted C1-6-alkyl and C3-7-cycloalkyl; each of R8 and R9 is independently hydrogen or optionally substituted C1-6-alkyl; or R8 and R9 together with the N to which they are attached form a C4-6-heterocycloalkyl; each R10 is selected from C3-7- cycloalkyl and optionally substituted C1-6-alkyl; each R11 is independently selected from C1-6-alkyl, C3-7-cycloalkyl, C1-6-alkyl-C3-7-cycloalkyl, C4-7-heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted; A is selected from halogen, - NR4S02R5, -CN, -OR6, -NR4R5, -NR7R11, hydroxyl, -CF3, -CONR4R5, -NR4COR5, -NR7(CO)NR4R5, -N02, -C02H, -C02R6, -S02R6, -S02NR4R5, -NR4COR5 ,-NR4COOR5, 6-alkyl and -COR6. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formulae la and lb.

  一种具有化学式la或化学式lb的化合物，或其在药学上可接受的盐或酯，其中R1选择自：芳基；杂环芳基；-NHR3；融合芳基-C4-7-杂环烷基；-CONR4R5；-NHCOR6；-C3-7-环烷基；-0-C3-7-环烷基；-NR3R6；以及可选择地取代的-C1-6烷基；其中所述的芳基、杂环芳基、融合芳基-C4-7-杂环烷基和C4-7-杂环烷基均可选择地取代；Q选择自CN、卤素，或选择自C1-6-烷基、C3-7-环烷基、杂环烷基、芳基和杂环芳基，每种均可选择地取代一个或多个取代基A；R2选择自氢、芳基、C1-6-烷基、C2-6-烯烃基、C3-7-环烷基、杂环芳基、C4-7-杂环烷基和卤素，其中所述的C1-6-烷基、C2-6-烯烃基、芳基、杂环芳基和C4-7-杂环烷基均可选择地取代；R3选择自芳基、杂环芳基、C4-7-杂环烷基、C3-7-环烷基、融合芳基-C-杂环烷基和C1-6-烷基，每种均可选择地取代；R4和R5各自独立地为氢，或可选择地取代的C3-7-环烷基、芳基、杂环芳基、C1-6-烷基或C3-6-杂环烷基；或R4和R5与其连接的N一起形成一个C3-6-杂环烷基环；每个R6独立地选择自C1-6-烷基、C3-7-环烷基、C-杂环烷基、芳基和杂环芳基，每种均可选择地取代；每个R7选择自氢、可选择地取代的C1-6-烷基和C3-7-环烷基；每个R8和R9各自独立地为氢或可选择地取代的C1-6-烷基；或R8和R9与其连接的N一起形成一个C4-6-杂环烷基；每个R10选择自C3-7-环烷基和可选择地取代的C1-6-烷基；每个R11独立地选择自C1-6-烷基、C3-7-环烷基、C1-6-烷基-C3-7-环烷基、C4-7-杂环烷基、芳基和杂环芳基，每种均可选择地取代；A选择自卤素、-NR4S02R5、-CN、-OR6、-NR4R5、-NR7R11、羟基、-CF3、-CONR4R5、-NR4COR5、-NR7(CO)NR4R5、-N02、-C02H、-C02R6、-S02R6、-S02NR4R5、-NR4COR5、-NR4COOR5、6-烷基和-COR6。进一步涉及到具有化学式la和lb的化合物的制药组合物、治疗用途和制备过程。